Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 115

Results For "brand"

1168 News Found

Remdesivir demand was exaggerated: Dr. Sharvil Patel
News | May 28, 2021

Remdesivir demand was exaggerated: Dr. Sharvil Patel

Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines


Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca
News | May 28, 2021

Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca

Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021


Pfizer registers Q4FY21net profit at Rs 100 Cr
News | May 26, 2021

Pfizer registers Q4FY21net profit at Rs 100 Cr

Revenue from operations for the year ended March 31, 2021 is ?2,239 crore


Bal Pharma launches BALflu, Favipiravir formulation in India
News | May 25, 2021

Bal Pharma launches BALflu, Favipiravir formulation in India

BALflu is approved by DCGI for emergency use for the treatment of COVID-19


Nanoform and Celanese explore ways to enhance drug delivery
News | May 25, 2021

Nanoform and Celanese explore ways to enhance drug delivery

Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.


NATCO Pharma receives USFDA approval for Lenalidomide capsules
Policy | May 24, 2021

NATCO Pharma receives USFDA approval for Lenalidomide capsules

NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.


Balaxi records Q4 FY21 revenue of Rs. 53 Cr
News | May 22, 2021

Balaxi records Q4 FY21 revenue of Rs. 53 Cr

Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday


Outlook promising for Cipla: HDFC Securities
News | May 18, 2021

Outlook promising for Cipla: HDFC Securities

The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.


Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
News | May 18, 2021

Outlook intact for Dr. Reddy's Laboratories : ICICI Securities

India sales grew 23.5% YoY with consolidation of Wockhardt products


Zydus Cadila entity to sell its India focused animal health business to a consortium
News | May 13, 2021

Zydus Cadila entity to sell its India focused animal health business to a consortium

The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,